Psychedelic highlights | June 07 – 11

Shares :

Psychedelic highlights | June 07 – 11

Here is a summary of the news from the last week in the psychedelics market. The value of the psychedelics market is more than $100 billion according to Cannacord most recent report.

Psychedelic market value by company

Last week performance

MindMedMMED$4.67+ 21.2 %
CompassCMPS$39.68+ 19.4 %
NuminusNUMI$1.03+ 14.44 %
Field TripFTRP$6.35+ 14.4 %
Red Light HollandsTRIP$0.36+ 14.2 %
Psykey inc.CEOS$0.138+ 6.8 %
Revive TherapeuticsRVV$0.47+ 6.8 %
Mind CureMCUR$0.395+ 3.9 %
Cybin Inc. CYBN$1.83+ 1.6 %
Psyched WellnessPSYC$0.27– 10 %
M2Bio SciencesWUHN$0.465– 27.3 %

Ticker : CEOS (OTC PINK)
Market Cap: $27 000 000
Current Share Price: $0.138

PsyKey Inc. is currently in the development stages of patentable cutting-edge novel technologies, that will directly support and impact the fast-evolving therapeutic psilocybin market. These technologies are focused on composition, bioavailability, and targeted delivery.

Read more HERE

Story of the week

1. Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India [news release]

Revive Therapeutics announce it has entered into a memorandum of understanding dated June 7, 2021 with Supriya Lifescience Ltd. (“Supriya”), a specialty pharmaceutical company based in India, to pursue manufacturing of the API, conducting clinical registration and commercialization for Bucillamine to treat COVID-19 through Emergency Use Authorization (“EUA”) in India.

Read the full news HERE

2. Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy [news release]

Cybin announced that it will co-sponsor a randomized, placebo-controlled trial of psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress. The study will aim to treat symptoms of depression, anxiety, burnout and post-traumatic stress . 

Read the full news HERE

3. MindMed Announces Chief Executive Officer Transition [news release]

MindMed Inc. announces that J.R. Rahn, the Company’s co-founder and chief executive officer, is stepping down as chief executive officer and a director, and that its chief development officer, Robert Barrow, will assume the position of chief executive officer with immediate effect. 

Read the full news HERE

4. American Journal of Psychiatry Publishes International Ketamine and Esketamine Treatment Guidance Led by Braxia Scientific CEO Dr. Roger Mcintyre [news release]

Braxia Scientific announce the American Journal of Psychiatry, the most widely read psychiatric journal in the world, has published the International Expert Opinion and Implementation Guidance (the “Guidelines”) for the clinical use of rapid-acting Ketamine and Esketamine for treatment-resistant depression (TRD).  

Read the full article HERE

5. PharmaTher Provides Research and Development Update and Milestones for 2021 [news release]

PharmaTher Inc. provide an update on the research and development initiatives of its psychedelic product programs and upcoming milestones for 2021.

Read the full news HERE

6. Entheon Biomedical’s Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US [news release]

Entheon announced its Psychedelics Genetic Test Kit, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc. (“HaluGen”), is now available for sale in the United States.

Read the full news HERE

7. Red Light Holland Closes Acquisition of Cutting Edge Silicon Valley Applied Sciences Company Radix Motion, Becoming a Leader in Psychedelic Technology and Closes Acquisition of 80% of Happy Caps Mushroom Farm [news release]

Red Light Holland’s  announce its wholly owned subsidiary, Red Light Acquisition Inc. (“Red Light US“) has acquired (the “Acquisition“) Radix Motion Inc. (“Radix Motion“), a technology and innovation company.

And announce that is has completed the acquisition of an 80% stake in 4316747 Nova Scotia Limited (“Happy Caps“). 

Read the full news HERE

Sign up for MORE news updates !

This article is written and published by The Cannabis Stock

Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Click on a star to rate this article !

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

Shares :